now half American, the manufacturer of Doliprane wants to reassure the production of the drug

The leaders of Opella Healthcare, who hold the Doliprane, an emblematic brand of French paracetamol, organized Thursday 19 June a communication operation by opening the doors of their Compiègne factory in the Oise. A month ago, Sanofi sold half of its subsidiary to the American pension fund CD&R. Unions and elected officials of all stripes are concerned about employment on the two French sites of Opella and the supply of Doliprane in France.

This production chain of the compiègne Opella site deletes doliprane boxes at high speed : eleven per second, one million every day counting the production of the other French site in Lisieux in Calvados.

If an American pension fund which has become the majority of the company, but management ensures that this does not change anything for French consumers: “I want to reassure all French people that Doliprane remains an emblematic French brandexplains the new owner of Opella France, Ségolène de Marsac. Doliprane remains produced in France, in Lisieux and Compiègne. 95% of Doliprane volumes are dedicated to France. So you see that it is almost all of the volumes of Doliprane that are available for France. “

With the arrival of this American majority shareholder, the other fear is to see the fly France’s health sovereignty and our ability to produce our drugs without depending on another country.

Sanofi had undertaken to provide paracetamol, the raw material of Doliprane, the active principle, with a new tricolor manufacturer: Sequens who will open a factory in Isère. Speech will be held by Opella, says the world industrial manager “We are going to supply ourselves as soon as Sequens can provide us at a height to start about 25 to 30%, but which can evolve much higher in the future”explains Rafik Amrane.

A supply at Sequens which is not 100% for mainly two reasons, explains the industrial manager :: “The first is that from a technical point of view, we need different types of paracetamol to be able to produce our different doliprane formulas, whether solid, liquid or other. And another reason which is very simple, is that if we want to ensure the supply of doliprane of the French without breaking of supply, we must try to avoid putting all our eggs in the same basket.”

Opella who invests in research and development on her two French sites, a new formula of Doliprane 1000 will soon be available and has been imagined in this factory in Compiègne. On his own, Doliprane, the second brand of the group worldwide, represents 70% of Opella sales in France.